Platforms for Testing MRD in CRC

Opinion
Video

Arvind N. Dasari, MD, MS, provides clinical insights on MRD testing modalities, highlighting factors that inform the decision on which platform to use in practice.

Recent Videos
Stacey A. Cohen, MD, and Daniel H. Ahn, DO, presenting slides
Stacey A. Cohen, MD, and Daniel H. Ahn, DO, presenting slides
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Stacey A. Cohen, MD, and Daniel H. Ahn, DO, presenting slides
Stacey A. Cohen, MD, and Daniel H. Ahn, DO, presenting slides
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
4 KOLs are featured in this panel.
4 KOLs are featured in this panel.
Related Content
The recommendation was made following mid-stage, end-of-phase 2 data for the botensilimab/balstilimab combination, which yielded lower responses in patients.

FDA Discourages Accelerated Approval of Botensilimab/Balstilimab Combo in R/R MSS CRC

Roman Fabbricatore
July 19th 2024
Article

The recommendation was made following mid-stage, end-of-phase 2 data for the botensilimab/balstilimab combination, which yielded lower responses in patients.

Oncology pharmacist Jagoda Misniakiewicz, PharmD, discusses the potential efficacy and safety profile of fruquintinib in patients with metastatic CRC.

Optimizing Metastatic CRC Outcomes Following Fruquintinib Approval

Jagoda Misniakiewicz, PharmD
June 10th 2024
Podcast

Oncology pharmacist Jagoda Misniakiewicz, PharmD, discusses the potential efficacy and safety profile of fruquintinib in patients with metastatic CRC.

The EA2201 trial assessed nivolumab plus ipilimumab and short-course radiation therapy for patients with locally advanced rectal cancer.

Nivolumab/Ipilimumab Plus RT Shows Promise in Locally Advanced Rectal Cancer

Ariana Pelosci
July 1st 2024
Article

The EA2201 trial assessed nivolumab plus ipilimumab and short-course radiation therapy for patients with locally advanced rectal cancer.

Surgical oncologists from Cleveland Clinic discuss the National Accreditation Program for Rectal Cancer and its aim to improve patient outcomes.

Ensuring Quality Rectal Cancer Surgery at NAPRC-Accredited Institutions

Steven Wexner, MD, PhD;Arielle Kanters, MD
May 27th 2024
Podcast

Surgical oncologists from Cleveland Clinic discuss the National Accreditation Program for Rectal Cancer and its aim to improve patient outcomes.

Data from FRESCO-2 support the approval of fruquintinib for those with previously treated metastatic colorectal cancer in the European Union.

European Commission Approves Fruquintinib in Pretreated Metastatic CRC

Russ Conroy
June 24th 2024
Article

Data from FRESCO-2 support the approval of fruquintinib for those with previously treated metastatic colorectal cancer in the European Union.

Data from the colorectal cancer cohort of the KRYSTAL-1 trial support the accelerated approval of adagrasib/cetuximab in KRAS G12C–mutated disease.

FDA Approves Adagrasib/Cetuximab in KRAS G12C-Mutated CRC

Ariana Pelosci
June 21st 2024
Article

Data from the colorectal cancer cohort of the KRYSTAL-1 trial support the accelerated approval of adagrasib/cetuximab in KRAS G12C–mutated disease.